MARKET

PHAR

PHAR

Pharming Group N.V.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.31
+0.51
+3.70%
After Hours: 14.30 -0.01 -0.07% 17:37 01/27 EST
OPEN
13.80
PREV CLOSE
13.80
HIGH
14.31
LOW
13.53
VOLUME
7.17K
TURNOVER
--
52 WEEK HIGH
21.99
52 WEEK LOW
13.50
MARKET CAP
913.06M
P/E (TTM)
231.18
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26)
Benzinga · 16h ago
The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 29)
Benzinga · 12/30/2020 13:08
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 12/29/2020 13:09
BRIEF-Pharming Group Q1 Operating Profit Up At 19.4 Million Euros
* PHARMING GROUP REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2020
Reuters · 05/14/2020 06:12
BRIEF-Pharming Group: EC Approves Ruconest For Treatment Of HAE Attacks In Children
* RECEIVES EUROPEAN COMMISSION APPROVAL FOR TREATMENT OF ACUTE HEREDITARY ANGIOEDEMA ATTACKS IN CHILDREN WITH RUCONEST
Reuters · 04/30/2020 06:40
BRIEF-Pharming Enters Euronext Amsterdam Midkap Index
* DESPITE UNCERTAINTY AROUND COVID-19, FOR NOW, WE DO NOT ANTICIPATE ANY ISSUES WITH REGARDS TO CONTINUOUS SUPPLY OF RUCONEST AND WE REMAIN CONFIDENT IN LONG-TERM PROSPECTS OF BUSINESS Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Reuters · 03/23/2020 06:08
BRIEF-Pharming CFO Robin Wright To Step Down
* ROBIN WRIGHT, HAS DECIDED (FOR FAMILY REASONS) NOT TO PUT HIMSELF UP FOR RE-ELECTION AS A MEMBER OF BOARD OF MANAGEMENT AND THUS AS CHIEF FINANCIAL OFFICER
Reuters · 03/11/2020 06:22
BRIEF-Pharming Group Receives FDA Approval Of New Facility For Expansion Of Ruconest® Production
* PHARMING GROUP NV SAYS RECEIVES FDA APPROVAL OF NEW FACILITY FOR EXPANSION OF RUCONEST® PRODUCTION
Reuters · 03/09/2020 06:11
More
Forecast
EPSBVPSCFPS
No Data
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHAR. Analyze the recent business situations of Pharming Group N.V. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Webull offers kinds of Pharming Group N.V. stock information, including NASDAQ:PHAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHAR stock methods without spending real money on the virtual paper trading platform.